摘要
Abstract
Objective To observe the clinical curative effect and prognosis of chronic heart failure standard therapy combined with erythropoietin (EPO) subcutaneous injection. Methods 60 patients with chronic heart failure were se lected, and randomly divided into the treatment group and the control group (conventional) 29 patients taking beta blockers + angiotensin 1-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (arbs) + diuretics, a serious symptoms of heart. 31 cases in treatment group were injected by 1001U/kg epithelial EPO, 1 time each week, treatment for six months. Echocardiography and routine blood were carried out for clinical observation before and after the treatment and mark the hospitalization period symptoms and mortality rates. Resulta After treatment, the left ventricular ejection fraction (LVEF) and hemoglobin (HB) concentrations were all improved, and left ventricular end-diastolic diameter (LVEDD) and left ventricular shrink diameter LVESD (final) were all narrow, but EPO group, compared with controls, showed significant difference on the symptoms period, mortality rates.Conclusion It shows thaterythropoietin can improve cardiac function in patients with chronic heart failure, and reduce the heart rate and mortality, and it's safe and effective for long-term use, clinical application research should be carried out.关键词
促红细胞生成素/慢性心衰/LVEF/再住院率Key words
Erythropoietin/Chronic heart failure/LVEF/Admission rates分类
医药卫生
